Desensitization would be considered for more severe presentations, such as when IgE-mediated anaphylaxis is strongly suspected, or when symptoms recur despite optimized baseline measures (H1 premedication and strict infusion-rate control), provided institutional capability exists [8,19]. Here, IGHE is linked to anaphylaxis.